Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Daniel Finley
Harvard Medical School, Department: Anatomy/cell Biology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Proteostasis Therapeutics, Inc.
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
The research is aimed in part at characterizing Usp14 and its regulation (one of three Aims). The Company, in collaboration with Biogen, is actively researching novel Usp14 inhibitors to enhance clearance of aggregation-prone proteins, such as α-synuclein in Parkinson’s disease and tau in Alzheimer’s disease among others. Thus, the research could have an impact on how USP14 inhibitors are eventually used.
Substrate recognition and processing by the proteasome
Project Narrative (Relevance Statement) The proteasome is the most important protease in all of nature, and exerts regulatory effects over many aspects of the biology of the cell. Our proposal is to investigate a small set of key proteasome regulators, several of which have been implicated in human disease. Our work may provide new insights in neurodegenerative disease, cancer, and developmental disorders.
Filed on January 05, 2017.
Tell us what you know about Daniel Finley's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Daniel Finley filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Daniel Finley | Harvard Medical School | Conflict of Interest | Proteostasis Therapeutics, Inc. | $20,000 - $39,999 |
| Daniel Finley | Harvard Medical School | Conflict of Interest | Proteostasis Therapeutics, Inc. | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.